Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1987 May;79(5):1524–1528. doi: 10.1172/JCI112983

Novobiocin enhances alkylating agent cytotoxicity and DNA interstrand crosslinks in a murine model.

J P Eder, B A Teicher, S A Holden, K N Cathcart, L E Schnipper
PMCID: PMC424429  PMID: 3033027

Abstract

DNA-DNA crosslinks are the lethal cellular mechanism of bifunctional alkylating agent cytotoxicity. Novobiocin, an inhibitor of DNA topoisomerase II, impairs eukaryotic DNA repair of alkylating agent adducts and may increase the number of adducts and their resultant cytotoxicity in malignant cells. The effect of novobiocin on clonogenic survival and DNA crosslinking due to cisplatin (cDDP) and carmustine (BCNU) was studied. Novobiocin caused synergistic cytotoxicity in Chinese hamster ovary cells exposed to cDDP or BCNU. Novobiocin and cDDP increased the formation of DNA-DNA interstrand crosslinks six-fold greater than cDDP alone. The effect was schedule dependent. Novobiocin and cDDP or BCNU markedly reduced in vivo growth of a murine fibrosarcoma without increased host toxicity. As a modulating agent of cytotoxicity due to DNA-DNA crosslinking, novobiocin may enhance the clinical effectiveness of the alkylating agents in human cancer and offer insight into new therapeutic strategies.

Full text

PDF
1524

Images in this article

1525Image
on p.1525
1526Image
on p.1526

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berenbaum M. C. Synergy, additivism and antagonism in immunosuppression. A critical review. Clin Exp Immunol. 1977 Apr;28(1):1–18. [PMC free article] [PubMed] [Google Scholar]
  2. Cotten M., Bresnahan D., Thompson S., Sealy L., Chalkley R. Novobiocin precipitates histones at concentrations normally used to inhibit eukaryotic type II topoisomerase. Nucleic Acids Res. 1986 May 12;14(9):3671–3686. doi: 10.1093/nar/14.9.3671. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Deen D. F., Williams M. E. Isobologram analysis of X-ray--BCNU interactions in vitro. Radiat Res. 1979 Sep;79(3):483–491. [PubMed] [Google Scholar]
  4. Dewey W. C., Stone L. E., Miller H. H., Giblak R. E. Radiosensitization with 5-bromodeoxyuridine of Chinese hamster cells x-irradiated during different phases of the cell cycle. Radiat Res. 1971 Sep;47(3):672–688. [PubMed] [Google Scholar]
  5. Edenberg H. J. Novobiocin inhibition of simian virus 40 DNA replication. Nature. 1980 Jul 31;286(5772):529–531. doi: 10.1038/286529a0. [DOI] [PubMed] [Google Scholar]
  6. Erickson L. C., Laurent G., Sharkey N. A., Kohn K. W. DNA cross-linking and monoadduct repair in nitrosourea-treated human tumour cells. Nature. 1980 Dec 25;288(5792):727–729. doi: 10.1038/288727a0. [DOI] [PubMed] [Google Scholar]
  7. Frei E., 3rd Curative cancer chemotherapy. Cancer Res. 1985 Dec;45(12 Pt 1):6523–6537. [PubMed] [Google Scholar]
  8. Gellert M., O'Dea M. H., Itoh T., Tomizawa J. Novobiocin and coumermycin inhibit DNA supercoiling catalyzed by DNA gyrase. Proc Natl Acad Sci U S A. 1976 Dec;73(12):4474–4478. doi: 10.1073/pnas.73.12.4474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Glikin G. C., Blangy D. In vitro transcription by Xenopus oocytes RNA polymerase III requires a DNA topoisomerase II activity. EMBO J. 1986 Jan;5(1):151–155. doi: 10.1002/j.1460-2075.1986.tb04189.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Holm C., Goto T., Wang J. C., Botstein D. DNA topoisomerase II is required at the time of mitosis in yeast. Cell. 1985 Jun;41(2):553–563. doi: 10.1016/s0092-8674(85)80028-3. [DOI] [PubMed] [Google Scholar]
  11. Lindahl T., Karran P., Demple B., Sedgwick B., Harris A. Inducible DNA repair enzymes involved in the adaptive response to alkylating agents. Biochimie. 1982 Aug-Sep;64(8-9):581–583. doi: 10.1016/s0300-9084(82)80091-6. [DOI] [PubMed] [Google Scholar]
  12. Liu L. F., Liu C. C., Alberts B. M. Type II DNA topoisomerases: enzymes that can unknot a topologically knotted DNA molecule via a reversible double-strand break. Cell. 1980 Mar;19(3):697–707. doi: 10.1016/s0092-8674(80)80046-8. [DOI] [PubMed] [Google Scholar]
  13. Mattern M. R., Scudiero D. A. Dependence of mammalian DNA synthesis on DNA supercoiling. III. Characterization of the inhibition of replicative and repair-type DNA synthesis by novobiocin and nalidixic acid. Biochim Biophys Acta. 1981 Apr 27;653(2):248–258. doi: 10.1016/0005-2787(81)90160-x. [DOI] [PubMed] [Google Scholar]
  14. Meechan P. J., Killpack S., Cleaver J. E. Novobiocin-mediated inhibition of polymerization and ligation of DNA in vitro. Mutat Res. 1984 Oct;141(2):69–73. doi: 10.1016/0165-7992(84)90013-7. [DOI] [PubMed] [Google Scholar]
  15. Meyn R. E., Jenkins S. F., Thompson L. H. Defective removal of DNA cross-links in a repair-deficient mutant of Chinese hamster cells. Cancer Res. 1982 Aug;42(8):3106–3110. [PubMed] [Google Scholar]
  16. Miller K. G., Liu L. F., Englund P. T. A homogeneous type II DNA topoisomerase from HeLa cell nuclei. J Biol Chem. 1981 Sep 10;256(17):9334–9339. [PubMed] [Google Scholar]
  17. Ross W., Rowe T., Glisson B., Yalowich J., Liu L. Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Res. 1984 Dec;44(12 Pt 1):5857–5860. [PubMed] [Google Scholar]
  18. Ryoji M., Worcel A. Chromatin assembly in Xenopus oocytes: in vivo studies. Cell. 1984 May;37(1):21–32. doi: 10.1016/0092-8674(84)90297-6. [DOI] [PubMed] [Google Scholar]
  19. Sedgwick B., Lindahl T. A common mechanism for repair of O6-methylguanine and O6-ethylguanine in DNA. J Mol Biol. 1982 Jan 5;154(1):169–175. doi: 10.1016/0022-2836(82)90424-7. [DOI] [PubMed] [Google Scholar]
  20. Setlow R. B. Repair deficient human disorders and cancer. Nature. 1978 Feb 23;271(5647):713–717. doi: 10.1038/271713a0. [DOI] [PubMed] [Google Scholar]
  21. Steel G. G., Peckham M. J. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys. 1979 Jan;5(1):85–91. doi: 10.1016/0360-3016(79)90044-0. [DOI] [PubMed] [Google Scholar]
  22. Tewey K. M., Chen G. L., Nelson E. M., Liu L. F. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem. 1984 Jul 25;259(14):9182–9187. [PubMed] [Google Scholar]
  23. Tewey K. M., Rowe T. C., Yang L., Halligan B. D., Liu L. F. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science. 1984 Oct 26;226(4673):466–468. doi: 10.1126/science.6093249. [DOI] [PubMed] [Google Scholar]
  24. Thomas C. B., Osieka R., Kohn K. W. DNA cross-linking by in vivo treatment with 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea of sensitive and resistant human colon carcinoma xenograms in nude mice. Cancer Res. 1978 Aug;38(8):2448–2454. [PubMed] [Google Scholar]
  25. Zwelling L. A., Michaels S., Schwartz H., Dobson P. P., Kohn K. W. DNA cross-linking as an indicator of sensitivity and resistance of mouse L1210 leukemia to cis-diamminedichloroplatinum(II) and L-phenylalanine mustard. Cancer Res. 1981 Feb;41(2):640–649. [PubMed] [Google Scholar]
  26. veer Reddy G. P., Pardee A. B. Inhibitor evidence for allosteric interaction in the replitase multienzyme complex. Nature. 1983 Jul 7;304(5921):86–88. doi: 10.1038/304086a0. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES